Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/7/2025

BIC/FTC/TAF for HIV Post-Exposure Prophylaxis

  • The CDC recommends BIC/FTC/TAF as a preferred regimen for adults and adolescents requiring PEP, administered as a single tablet once daily for 28 days for complete HIV post-exposure prophylaxis 1, 2, 4
  • BIC/FTC/TAF is available as a fixed-dose combination (FDC) tablet, making it a complete single-tablet regimen 1, 5

Evidence Supporting BIC/FTC/TAF for PEP

  • Clinical studies have demonstrated high completion rates (90-96%) with BIC/FTC/TAF PEP regimens 2
  • BIC/FTC/TAF has shown significantly higher completion rates compared to earlier PEP regimens, including Zidovudine/lamivudine plus a protease inhibitor (38.8%) 5, twice daily raltegravir plus TDF/FTC (57.0%) 2, and co-formulated elvitegravir/cobicistat/TDF/FTC (71.0%) 2

Important Clinical Considerations

  • The CDC recommends initiating PEP as soon as possible after exposure, preferably within 1-2 hours, but can be started up to 72 hours post-exposure 3
  • HIV testing should be performed before initiating PEP and at follow-up intervals (4-6 weeks and 12 weeks after exposure) 3
  • PEP can be discontinued if the source is found to be HIV-negative at any point during the course 3

Special Populations

  • The CDC recommends BIC/FTC/TAF as a preferred regimen for children aged ≥2 years and weighing ≥14 kg 1, 5
  • For pregnant women, the recommended ART regimen is dolutegravir with TAF/FTC, according to Praxis Medical Insights 6

Common Pitfalls to Avoid

  • Mistaking PEP for a single-dose intervention, when it requires a full 28-day course, as emphasized by the CDC 1, 2
  • Delaying initiation beyond 72 hours post-exposure reduces effectiveness, as noted by Praxis Medical Insights 3
  • Failing to check for drug interactions, particularly with medications containing polyvalent cations, is a common pitfall to avoid, according to Praxis Medical Insights 6